Search

Additional analysis of real-world data confirms sequential Gilotrif® followed by osimertinib provided a median overall survival of nearly four years in U.S.-treated patients with EGFR mutation-positive NSCLC

Additional analysis of real-world data confirms sequential Gilotrif® followed by osimertinib provided a median overall survival of nearly four years in U.S.-treated patients with EGFR mutation-positive NSCLC

FDA Approves Pradaxa® (dabigatran etexilate) for DVT & PE | BI US

FDA approves PRADAXA for the prophylaxis of DVT & PE in patients who have undergone a hip replacement. View ISI, PI and Med Guide.

New analysis supports long-term treatment with Ofev® in SSc-ILD patients

FDA Approves Pradaxa, Marking a Major Milestone to Reduce the Risk of Stroke in Patients with Non-Valvular Atrial Fibrillation

Phase III InPedILD™ trial enrolls first patient to evaluate nintedanib in pediatric population with fibrosing interstitial lung disease

Phase III study showed Ofev® slows the loss of pulmonary function in people living with systemic sclerosis associated ILD

Phase III study showed Ofev slows the loss of pulmonary function in people living with systemic sclerosis associated ILD

Study analysis available during ATS 2021 supports long-term treatment with Ofev® in patients with systemic sclerosis-associated interstitial lung disease

Pradaxa® (dabigatran etexilate mesylate) Capsules Gains Preferred Formulary Status with AARP®, Nation's Largest Provider of Medicare Part D Coverage

Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events

New Study Results Published in the New England Journal of Medicine Show Dabigatran Etexilate Mesylate Reduces the Risk of Recurrent Venous Thromboembolism

STIOLTO® RESPIMAT® (tiotropium bromide) Available in US | BI US

Read more about the newly available medication for COPD, STIOLTO RESPIMAT, proven to support both treatment and management of the disease.

Dortmund

The site in Dortmund plays a key role in manufacturing the propellant-free inhaler RESPIMAT® as well as all other products within the RESPIMAT

FDA Advisory Committee Recommends Approval of Ofev® for the Treatment of Systemic Sclerosis Associated ILD

Final analysis of the observational GioTag study: Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small cell lung cancer

Real-world study shows sequencing of Gilotrif® followed by osimertinib delivered a combined median time on treatment of 27.6 months in patients with EGFR mutation-positive NSCLC

Real-world study shows sequencing of Gilotrif

FDA approves Ofev® as first treatment for chronic fibrosing ILDs with a progressive phenotype

Updated real-world data show Gilotrif® followed by osimertinib provided a median overall survival of up to almost four years in patients with EGFR Del19 and T790M mutation-positive NSCLC

New Jardiance® (empagliflozin) data show improved CV outcomes regardless of heart failure status at baseline

U.S. FDA Approves Once-daily Jentadueto® XR (linagliptin and metformin hydrochloride extended-release) Tablets for Adults with Type 2 Diabetes

Efficacy and safety maintained in patients who switched from Humira® to biosimilar Cyltezo®

New Long-Term Data Published in Circulation Reinforce Safety Profile of Pradaxa® (dabigatran etexilate mesylate)

US FDA grants Fast Track designation to Jardiance® (empagliflozin) to improve outcomes following a heart attack

FDA grants Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease

Results from the INJOURNEY™ trial investigating Ofev® with add-on pirfenidone provide new insights into this combination treatment for IPF

Real-world analysis reinforces that Gilotrif® dose adjustments reduce the frequency and intensity of adverse drug reactions without impacting efficacy

dose adjustments reduce the frequency and intensity of adverse

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers

Search

Additional analysis of real-world data confirms sequential Gilotrif® followed by osimertinib provided a median overall survival of nearly four years in U.S.-treated patients with EGFR mutation-positive NSCLC

FDA Approves Pradaxa® (dabigatran etexilate) for DVT & PE | BI US

New analysis supports long-term treatment with Ofev® in SSc-ILD patients

FDA Approves Pradaxa, Marking a Major Milestone to Reduce the Risk of Stroke in Patients with Non-Valvular Atrial Fibrillation

Phase III InPedILD™ trial enrolls first patient to evaluate nintedanib in pediatric population with fibrosing interstitial lung disease

Phase III study showed Ofev® slows the loss of pulmonary function in people living with systemic sclerosis associated ILD

Study analysis available during ATS 2021 supports long-term treatment with Ofev® in patients with systemic sclerosis-associated interstitial lung disease

Pradaxa® (dabigatran etexilate mesylate) Capsules Gains Preferred Formulary Status with AARP®, Nation's Largest Provider of Medicare Part D Coverage

Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events

New Study Results Published in the New England Journal of Medicine Show Dabigatran Etexilate Mesylate Reduces the Risk of Recurrent Venous Thromboembolism

STIOLTO® RESPIMAT® (tiotropium bromide) Available in US | BI US

Dortmund

FDA Advisory Committee Recommends Approval of Ofev® for the Treatment of Systemic Sclerosis Associated ILD

Final analysis of the observational GioTag study: Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small cell lung cancer

Real-world study shows sequencing of Gilotrif® followed by osimertinib delivered a combined median time on treatment of 27.6 months in patients with EGFR mutation-positive NSCLC

FDA approves Ofev® as first treatment for chronic fibrosing ILDs with a progressive phenotype

Updated real-world data show Gilotrif® followed by osimertinib provided a median overall survival of up to almost four years in patients with EGFR Del19 and T790M mutation-positive NSCLC

New Jardiance® (empagliflozin) data show improved CV outcomes regardless of heart failure status at baseline

U.S. FDA Approves Once-daily Jentadueto® XR (linagliptin and metformin hydrochloride extended-release) Tablets for Adults with Type 2 Diabetes

Efficacy and safety maintained in patients who switched from Humira® to biosimilar Cyltezo®

New Long-Term Data Published in Circulation Reinforce Safety Profile of Pradaxa® (dabigatran etexilate mesylate)

US FDA grants Fast Track designation to Jardiance® (empagliflozin) to improve outcomes following a heart attack

FDA grants Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease

Results from the INJOURNEY™ trial investigating Ofev® with add-on pirfenidone provide new insights into this combination treatment for IPF

Real-world analysis reinforces that Gilotrif® dose adjustments reduce the frequency and intensity of adverse drug reactions without impacting efficacy